The DOI matches its Crossref record.
Paracetamol: Past, Present, and Future
Abstract
Paracetamol (acetaminophen) is one of the most widely used of all drugs, with a wealth of experience clearly establishing it as the standard antipyretic and analgesic for mild to moderate pain states. First used clinically by von Mering in 1893, paracetamol did not appear commercially until 1950 in the United States and 1956 in Australia. During the 1960s and 1970s, increasing concern was raised about the toxicity of nonprescription analgesics, but in normal use paracetamol exhibited a consistent safety profile. Its exemplary safety record was marred by the discovery in 1966 that a major overdose could be complicated by severe and sometimes fatal liver damage. Fortunately, early treatment with N-acetylcysteine prevents liver toxicity. A turning point in the choice of pediatric analgesic came in the 1980s when aspirin was linked to Reye's syndrome. As a consequence, paracetamol became the mainstay analgesic and antipyretic for children with a subsequent reduction in the incidence of Reye's syndrome. Currently, paracetamol is a first-line choice for pain management and antipyresis in a variety of patients, including children, pregnant women, the elderly, those with osteoarthritis, simple headaches, and those with noninflammatory musculoskeletal conditions. With proper use, paracetamol seldom causes adverse events and reports of serious side effects are rare. It has a broad tolerability and is of particular value in the treatment of patients in whom nonsteroidal anti-inflammatory drugs are contraindicated such as aspirin-sensitive asthmatics and people at risk of gastrointestinal complications. In the future, a better insight into the mechanism of action of paracetamol may be gained from a fuller understanding of the cyclooxygenase enzymes. In the meantime, paracetamol may find applications in other therapeutic areas, such as the prevention of atherosclerosis via a potential antioxidant activity. In summary, although it is more than a century since the first clinical use of paracetamol, it continues to be a first-line therapy of choice in adults and children with fever and pain. In addition, current research suggests that paracetamol may have a much broader clinical utility in years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early clinical investigations suggested that paracetamol possessed antipyretic properties but was associated with adverse hematological effects, a conclusion that contributed to the drug’s prolonged neglect and later proved erroneous [ 6 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [6]
In the citing paper
“By the 1970s and 1980s, it had largely supplanted both acetanilide and phenacetin in clinical practice, establishing itself as the reference non-opioid analgesic in many countries [ 5 , 6 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [6]
In the citing paper
“leading to its commercial introduction in the United States in 1950 and progressively throughout Europe during the following decade [ 6 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [6]
In the citing paper
“Early clinical investigations suggested that paracetamol possessed antipyretic properties but was associated with adverse hematological effects, a conclusion that contributed to the drug’s prolonged neglect and later proved erroneous [ 6 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [6]
Citations
Cites
Still being checked.
Cited by
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing
Deweese, J. E., & Osheroff, N. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn937 · Cited by 462
Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?
Warner, T. D., & Mitchell, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222543099 · Cited by 302
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action
Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223
Perioperative Pain Management and Opioid Stewardship: A Practical Guide
Hyland, S. J., Brockhaus, K. K., Vincent, W. R., Spence, N. Z., Lucki, M. M., Howkins, M. J., & Cleary, R. K. (2021) · Healthcare · doi:10.3390/healthcare9030333 · Cited by 206
Metadata
- Authors
- Prescott, L. F.
- Affiliations
- University of Edinburgh (GB)
- Corresponding author
- Prescott, Laurie F.
- ORCID
- Prescott, Laurie F.
- Venue
- American Journal of Therapeutics
- Published
- 2000-03
- Volume
- 7
- Issue
- 2
- Pages
- 143-148
- ISSN
- 1075-2765 (ISSN-L)
- OpenAlex
- W2040447399
- Cited by
- 233
- References
- 0
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 13 · 2023: 16 · 2022: 9 · 2021: 15 · 2020: 11 · 2019: 12 · 2018: 6 · 2017: 3 · 2016: 7 · 2015: 9 · 2014: 5 · 2013: 9 · 2012: 3
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Keywords
- paracetamol, antipyretics, analgesics, Reye's syndrome, aspirin, N-acetylcysteine, hepatotoxicity, pediatric analgesia, drug safety, cyclooxygenase, atherosclerosis prevention, antioxidant activity
- MeSH terms
- Acetaminophen, Fever, Humans, Pain, Analgesics, Non-Narcotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paracetamol: Past, Present, and Future. https://app.cochat.ai/papers/10.1097/00045391-200007020-00011
- The paper
- Prescott, L. F. (2000). Paracetamol: Past, Present, and Future. American Journal of Therapeutics. https://doi.org/10.1097/00045391-200007020-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.